Drug Patents owned by Astellas

1. Drug name - CRESEMBA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6812238 ASTELLAS N-substituted carbamoyloxyalkyl-azolium derivatives
Oct, 2025

(3 years from now)

CN1185230C ASTELLAS N-Substituted Carbamoyl Oxy Alkyl-Pyrrole Derivatives
Oct, 2020

(1 year, 11 months ago)

CN1387529A ASTELLAS N-Substituted Carbamoyl Oxy Alkyl-Pyrrole Derivatives
Oct, 2020

(1 year, 11 months ago)

EP1280795B1 ASTELLAS N-Substituted Carbamoyloxyalkyl-Azolium Derivatives
Oct, 2020

(1 year, 11 months ago)

EP1280795A2 ASTELLAS N-Substituted Carbamoyloxyalkyl-Azolium Derivatives
Oct, 2020

(1 year, 11 months ago)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10206879 ASTELLAS Active ingredient containing stabilised solid forms and method for the production thereof Sep, 2027

(4 years from now)

US10603280 ASTELLAS Active ingredient containing stabilised solid medicinal forms and methods for the production thereof Sep, 2027

(4 years from now)

More Information on Dosage
Strength Dosage Availability
372MG POWDER;INTRAVENOUS Prescription

2. Drug name - LEXISCAN

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6403567 ASTELLAS N-pyrazole A2A adenosine receptor agonists
Apr, 2022

(5 months ago)

US8106183 ASTELLAS Process for preparing an A2A-adenosine receptor agonist and its polymorphs
Feb, 2027

(4 years from now)

CN101379073A ASTELLAS Method For Preparing An A2A-Adenosine Receptor Agonist And Its Polymorphs
Apr, 2013

(9 years ago)

CN102260311A ASTELLAS Method For The Preparation Of A Type 2A Adenosine Receptor Agonist And Its Polymorphs Thing
Mar, 2015

(7 years ago)

CN1358191A ASTELLAS N-Pyrazole A
Jun, 2020

(2 years ago)

CN1167709C ASTELLAS N-Pyrazole A
Jun, 2020

(2 years ago)

EP1189916B1 ASTELLAS N-Pyrazole A 2A Receptor Agonists
Jun, 2025

(2 years from now)

EP1189916A2 ASTELLAS N-Pyrazole A 2A Receptor Agonists
Jun, 2025

(2 years from now)

EP1989214B8 ASTELLAS Process For Preparing An A2A-Adenosine Receptor Agonist And Its Polymorphs
Feb, 2027

(4 years from now)

EP1989214A1 ASTELLAS Process For Preparing An A2A-Adenosine Receptor Agonist And Its Polymorphs
Feb, 2027

(4 years from now)

EP1989214B1 ASTELLAS Process For Preparing An A2A-Adenosine Receptor Agonist And Its Polymorphs
Feb, 2027

(4 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
USRE47301 ASTELLAS Process for preparing an A2A-adenosine receptor agonist and its polymorphs Feb, 2027

(4 years from now)

Drugs and Companies using REGADENOSON ingredient

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
0.4MG/5ML (0.08MG/ML) SOLUTION;INTRAVENOUS Prescription

3. Drug name - VESICARE LS

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9918970 ASTELLAS Pharmaceutical composition comprising solifenacin May, 2031

(8 years from now)

More Information on Dosage
Strength Dosage Availability
1MG/ML SUSPENSION;ORAL Prescription

4. Drug name - XOSPATA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8969336 ASTELLAS Diamino heterocyclic carboxamide compound
Jan, 2031

(8 years from now)

CN102421761B ASTELLAS Two Heterocyclic Carboxamide Compounds
May, 2030

(7 years from now)

CN102421761A ASTELLAS Diamino Heterocyclic Carboxamide Compound
May, 2030

(7 years from now)

IN292990B ASTELLAS Diamino Heterocyclic Carboxamide Compound
May, 2030

(7 years from now)

IN201108996P4 ASTELLAS Diamino Heterocyclic Carboxamide Compound
May, 2030

(7 years from now)

EP3009428B1 ASTELLAS Diamino Heterocyclic Carboxamide Compound
May, 2030

(7 years from now)

EP3009428A1 ASTELLAS Diamino Heterocyclic Carboxamide Compound
May, 2030

(7 years from now)

EP2428508A4 ASTELLAS Diamino Heterocyclic Carboxamide Compound
May, 2030

(7 years from now)

EP2428508A1 ASTELLAS Diamino Heterocyclic Carboxamide Compound
May, 2030

(7 years from now)

EP2428508B1 ASTELLAS Diamino Heterocyclic Carboxamide Compound
May, 2030

(7 years from now)

EP2428508B9 ASTELLAS Diamino Heterocyclic Carboxamide Compound
May, 2030

(7 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9487491 ASTELLAS Diamino heterocyclic carboxamide compound Jul, 2030

(7 years from now)

US10786500 ASTELLAS Stable pharmaceutical composition for oral administration Jul, 2036

(13 years from now)

Drugs and Companies using GILTERITINIB FUMARATE ingredient

Treatment: Treatment of acute myeloid leukemia (aml)

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 40MG BASE TABLET;ORAL Prescription

5. Drug name - XTANDI

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7709517 ASTELLAS Diarylhydantoin compounds
Aug, 2027

(4 years from now)

CN102584712A ASTELLAS Diaryl Hydantoin Compound
Nov, 2015

(6 years ago)

CN105037273A ASTELLAS Diaryl Hydantoin Compound
Mar, 2026

(3 years from now)

CN101222922B ASTELLAS Diaryl Hydantoin Compounds
Mar, 2026

(3 years from now)

CN105037273B ASTELLAS Diaryl Hydantoin Compound
Mar, 2026

(3 years from now)

CN101222922A ASTELLAS Diarylhydantoin Compounds
Mar, 2026

(3 years from now)

CN101460467B ASTELLAS Diarylthiohydantoin Compound
Mar, 2027

(4 years from now)

CN101460467A ASTELLAS Diarylthiohydantoin Compounds
Mar, 2027

(4 years from now)

CN102755318B ASTELLAS Diarylthiohydantoin Compound
Mar, 2027

(4 years from now)

CN102755318A ASTELLAS Diaryl Thiohydantoin Compounds
Mar, 2027

(4 years from now)

EP2444085A1 ASTELLAS Diarylhydantoin Compounds As Androgen Receptor Antagonists For Treatment Of Cancer
Jun, 2016

(6 years ago)

EP2444085B1 ASTELLAS Diarylhydantoin Compounds As Androgen Receptor Antagonists For Treatment Of Cancer
Jun, 2016

(6 years ago)

EP1893196B1 ASTELLAS Diarylhydantoin Compound
Mar, 2026

(3 years from now)

EP1893196A1 ASTELLAS Diarylhydantoin Compound
Mar, 2026

(3 years from now)

EP1893196A4 ASTELLAS Diarylhydantoin Compounds
Mar, 2026

(3 years from now)

EP1893196B2 ASTELLAS Diarylhydantoin Compound
Mar, 2026

(3 years from now)

EP2656842A3 ASTELLAS Androgen Receptor Modulator For The Treatment Of Prostate Cancer And Androgen Receptor-Associated Diseases
Mar, 2027

(4 years from now)

EP2013187A2 ASTELLAS Diarylthiohydantoin Compounds
Mar, 2027

(4 years from now)

EP2013187B1 ASTELLAS Diarylthiohydantoin Compounds
Mar, 2027

(4 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9126941 ASTELLAS Treatment of hyperproliferative disorders with diarylhydantoin compounds May, 2026

(3 years from now)

US8183274 ASTELLAS Treatment of hyperproliferative disorders with diarylhydantoin compounds Aug, 2026

(3 years from now)

Drugs and Companies using ENZALUTAMIDE ingredient

Treatment: The treatment of patients with metastatic castration-sensitive prostate cancer; treatment of patients with castration-resistant prostate cancer (crpc); The treatment of patients with metastatic castration-resistant prostate cancer who have previously received docetaxel; the treatment of patients with metastatic castration-resistant prostate cancer (crpc).; the treatment of patients with metastatic castration-sensitive prostate cancer; treatment of patients with castration-resistant prostate cancer (crpc)

Dosage: CAPSULE;ORAL

More Information on Dosage
Strength Dosage Availability
40MG CAPSULE;ORAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.